We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
-0.05%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$381M
AUM Growth
-$49.9M
Cap. Flow
-$22.9M
Cap. Flow %
-6%
Top 10 Hldgs %
22.14%
Holding
176
New
41
Increased
28
Reduced
15
Closed
51

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$4.48M
2
FLUX icon
Flux Power
FLUX
+$4.41M
3
XFOR icon
X4 Pharmaceuticals
XFOR
+$4.41M
4
AFMD
Affimed
AFMD
+$4.38M
5
CLDX icon
Celldex Therapeutics
CLDX
+$4.31M

Top Sells

Rank Stock Value
1
PALI icon
Palisade Bio
PALI
+$7.43M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$7.11M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.25M
4
EPIX
ESSA Pharma
EPIX
+$6.1M
5
ECOR icon
electroCore
ECOR
+$5.95M

Sector Composition

Rank Sector Weight
1 Healthcare 81.97%
2 Financials 5.73%
3 Technology 2.04%
4 Industrials 1.47%
5 Communication Services 1.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LAAA
76
DELISTED
Lakeshore Acquisition I Corp. Ordinary Shares
LAAA
$1.97M 0.52%
+200,000
New +$1.94M
KALV
77
DELISTED
KalVista Pharmaceuticals
KALV
$1.95M 0.51%
111,834
– –
JYAC
78
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$1.95M 0.51%
200,000
– –
ELOX
79
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$1.82M 0.48%
27,950
+11,197
+67% +$690K
ONCR
80
DELISTED
Oncorus, Inc.
ONCR
$1.79M 0.47%
+192,054
New +$2.19M
LFMD icon
81
LifeMD
LFMD
$172M
$1.79M 0.47%
+288,700
New +$2.46M
CMRX
82
DELISTED
Chimerix, Inc.
CMRX
$1.74M 0.46%
+281,790
New +$1.94M
VINC
83
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.74M 0.46%
5,381
– –
HLMN icon
84
Hillman Solutions
HLMN
$1.79B
$1.69M 0.44%
+142,000
New +$1.74M
ALP
85
Alpha Compute
ALP
$4.51M
$1.52M 0.4%
3,750
– –
EIGR
86
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.32M 0.35%
6,583
– –
VRPX
87
DELISTED
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
$1.3M 0.34%
+1,087
New +$2.28M
FATBW
88
DELISTED
FAT Brands Inc. Warrant
FATBW
$1.3M 0.34%
227,000
-6,697
-3% -$46.2K
BURU
89
DELISTED
NUBURU INC
BURU
$1.26M 0.33%
643
– –
PODD icon
90
Insulet
PODD
$9.79B
$1.21M 0.32%
4,250
-12,750
-75% -$3.64M
ACET icon
91
Adicet Bio
ACET
$74.7M
$1.12M 0.29%
8,893
– –
QNGY
92
DELISTED
Quanergy Systems, Inc.
QNGY
$1.11M 0.29%
5,560
– –
SNAX
93
DELISTED
Stryve Foods, Inc. Class A Common Stock
SNAX
$1.07M 0.28%
+13,333
New +$1.52M
PRQR icon
94
ProQR Therapeutics
PRQR
$265M
$1.05M 0.27%
+125,000
New +$817K
ACHV icon
95
Achieve Life Sciences
ACHV
$683M
$1.04M 0.27%
122,000
– –
FRGE
96
DELISTED
Forge Global Holdings
FRGE
$1.01M 0.27%
6,807
– –
ARYE
97
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$1M 0.26%
+100,000
New +$993K
BLSA
98
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$996K 0.26%
100,000
– –
FMAC
99
DELISTED
FirstMark Horizon Acquisition Corp.
FMAC
$980K 0.26%
100,000
– –
OMEG
100
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$974K 0.26%
100,000
– –
2 3
4
5 6

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Altium Capital Management held 176 positions worth $381M, down 12% from $431M the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Altium Capital Management withdrew a net $22.9M in Q3 2021, closing 51 positions and reducing 15 holdings. Its most notable exit was Palisade Bio, an estimated $7.43M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 85% a quarter earlier, followed by Financials and Technology.

Against the trend, Altium Capital Management opened a new position in Keros Therapeutics worth $4.99M.

  • Altium Capital Management's largest Q3 2021 buy was Keros Therapeutics: 126,000 shares worth $4.99M.
  • Altium Capital Management added most to Celldex Therapeutics in Q3 2021, an estimated $4.31M increase.
  • Altium Capital Management's biggest Q3 2021 reduction was Crinetics Pharmaceuticals, cutting an estimated $7.11M.
  • Altium Capital Management fully exited Palisade Bio in Q3 2021, selling an estimated $7.43M.
  • Altium Capital Management's ten largest holdings make up 22% of its $381M portfolio in Q3 2021.
  • Altium Capital Management opened 41 new positions and closed 51 in Q3 2021.
  • Altium Capital Management's portfolio value fell 12% quarter-over-quarter to $381M.

Based on Altium Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.